RNACCartesian Therapeutics, Inc.同业对比
Cartesian Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNAC本股 | $242M#6 | — | — | 605.5x#8 | -99.0%#8 | -68.3%#13 | -35851.3%#8 | — | — | — | — | — |
| CUE | $260M#2 | — | 112.3x#11 | 9.4x#6 | 195.7%#2 | 34.6%#5 | -96.7%#5 | -1151.6%#11 | — | — | 61.7%#3 | — |
| GLSI | $255M#3 | — | 81.8x#10 | — | — | -11.2%#10 | — | -621.1%#10 | — | — | — | — |
| FHTX | $250M#4 | — | — | 8.1x#5 | 36.8%#4 | 14.2%#8 | -279.5%#6 | — | — | — | -13.4%#5 | — |
| AKBA | $244M#5 | — | 9.8x#9 | 1.0x#3 | 47.5%#3 | 92.4%#3 | 9.9%#3 | -21.2%#5 | — | — | — | — |
| ALXO | $241M#7 | — | 1.8x#7 | — | — | 24.6%#6 | — | -74.7%#7 | -84.4%#1 | — | — | — |
| WHWK | $235M#8 | — | 1.3x#3 | 32.9x#7 | -72.5%#7 | 67.7%#4 | -1601.1%#7 | -11.3%#4 | — | — | 110.2%#2 | — |
| NATR | $232M#9 | 13.2x#1 | 1.7x#6 | 0.5x#1 | 5.7%#5 | 153.7%#1 | 5.2%#4 | 14.3%#2 | — | 9#1 | -19.9%#6 | — |
| ZNTL | $221M#10 | — | 1.5x#5 | — | -100.0%#9 | 17.4%#7 | — | -95.4%#8 | — | — | 116.9%#1 | — |
| SIGA | $220M#11 | — | 1.3x#4 | 2.3x#4 | -31.8%#6 | -60.7%#12 | 25.1%#2 | 14.1%#3 | — | — | -57.8%#8 | 19.6%#1 |
| KROS | $220M#12 | — | 0.8x#2 | 0.9x#2 | 6775.0%#1 | 146.4%#2 | 27.7%#1 | 33.2%#1 | — | — | -28.9%#7 | — |
| ELDN | $215M#13 | — | 6.5x#8 | — | — | -26.1%#11 | — | -138.2%#9 | — | — | — | — |
| BRVE | $2.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| NKTX | $201M#14 | — | 0.8x#1 | — | — | 4.3%#9 | — | -42.0%#6 | — | — | 45.8%#4 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议